The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025.
Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period.
According to an article published in the National Center for Biotechnology Information in 2015, pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period.
North America dominated the segment with the largest revenue share in 2015 due to high adoption rate of advanced treatment options and highly developed healthcare infrastructure. Asia Pacific is anticipated to show a significant growth during the forecast period, mainly due to increasing government initiatives, growing awareness regarding the treatment options for pancreatic cancer, and the availability of highly sophisticated medical infrastructure for effective treatment.
- Eli Lily and Company
- Celgene Corporation
- Hoffmann-La Roche AG
- Amgen, Inc.
- Novartis AG
- PharmaCyte Biotech, Inc.
- Clovis Oncology
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
Key Topics Covered:
1 Research Methodology
2 Executive Summary
3 Pancreatic Cancer Treatment Market Variables, Trends & Scope
4 Pancreatic Cancer Treatment Market: Affected Region Estimates & Trend Analysis
5 Pancreatic Cancer Treatment Market: Treatment Estimates & Trend Analysis
6 Pancreatic Cancer Treatment Market: Regional Estimates & Trend Analysis, by Affected region & Application
7 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/5b9jg3/pancreatic_cancer